Market research
PPCB Propanc Biopharma, Inc. Common Stock
NASDAQ USD Healthcare
Latest close
As of 30 Oct 2026
Test a moving-average rule with historical data.
Market facts
- Market cap
- 3M
- P/E ratio
- Not available
- Analyst target
- 1.52
- Dividend yield
- Not available
- Beta
- 3.33
Profile
Instrument facts
- Exchange
- NASDAQ
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- Not available
- Market cap
- 3M
- P/E ratio
- Not available
- Analyst target
- 1.52
- Dividend yield
- Not available
- Beta
- 3.33
About
About Propanc Biopharma, Inc. Common Stock
Propanc Biopharma, Inc., a development-stage biopharmaceutical healthcare company, engages in the development of cancer treatments for patients with pancreatic, ovarian, and colorectal cancers in Australia. Its lead product candidate is PRP, an intravenous injection proenzyme treatment designed as a therapeutic option in cancer treatment and prevention which has completed pre-clinical studies. The company has a research and collaboration agreement with the University of Jaén, to undertake research activities for the POP1 Program and the University of Granada to develop a synthetic recombinant version of PRP. Propanc Biopharma, Inc. was formerly known as Propanc Health Group Corporation and changed its name to Propanc Biopharma, Inc. in April 2017. The company was incorporated in 2007 and is based in Camberwell, Australia.
Research context
Propanc Biopharma, Inc. Common Stock appears in PyInvesting’s US Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
Community
Investor discussion
0 comments
Sign in to join the PPCB discussion.
No comments yet
Start a focused discussion about PPCB.